European Ad Comm backs Glaxo’s stem cell therapy Strimvelis for rare autoimmune disorder – Seeking Alpha
Fox News |
European Ad Comm backs Glaxo's stem cell therapy Strimvelis for rare autoimmune disorder
Seeking Alpha The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of GlaxoSmithKline's (GSK -0.9%) Strimvelis (GSK2696273) for the treatment of patients with ADA-SCID (severe … GSK receives European and CHMP approval for stem cell gene therapy UPDATE: Glaxo (GSK) Receives Positive EMA CHMP Opinion for Strimvelis as ADA-SCID Treatment |
